mug95 Antibody

What is M195 antibody and what cellular markers does it recognize?

M195 is a mouse IgG2a monoclonal antibody that recognizes a myelomonocytic differentiation antigen found on early myeloid cells and monocytes. The antibody binds to an antigen that appears related to CD33, though potentially to a different epitope on the same protein. Specifically, M195 demonstrates high affinity for myeloid lineage precursors while showing minimal reactivity with mature granulocytic elements and adult tissues, making it particularly valuable for detecting immature myeloid cells in research and diagnostic applications.

How does M195 antibody compare with other myeloid markers such as CD33 (MY9)?

M195 shows a similar but non-identical reactivity pattern to MY9 (CD33), with approximately 83% concordance in tested leukemia cases. The differences are significant for research purposes: cross-blocking studies demonstrate that M195 binding can be blocked by MY9 and L4F3 (both CD33 antibodies), suggesting M195 targets a distinct epitope on the same protein antigen. Importantly, when both MY9 and M195 positivity are present on a leukemia sample, there is a 98% specificity for diagnosing ANLL, which exceeds the specificity of either MY9 alone (88%) or M195 alone (92%).

What is the reactivity profile of M195 across different hematological malignancies?

M195 demonstrates a distinctive reactivity pattern across various hematological malignancies as shown in Table 1:

This reactivity profile makes M195 particularly valuable for distinguishing myeloid from lymphoid leukemias and identifying specific subtypes of myeloid malignancies.

What are the optimal flow cytometry protocols for M195 antibody detection?

For optimal M195 antibody detection via flow cytometry, researchers should follow these methodological guidelines:

• Sample preparation: Fresh hematopoietic samples (blood or bone marrow) should be processed within 24 hours of collection. Mononuclear cells should be isolated via density gradient centrifugation and washed in PBS containing 2% FBS.

• Antibody staining: Incubate 1×10^6 cells with appropriately titrated M195 antibody (typically 1-5 μg/mL) for 30 minutes at 4°C protected from light.

• Washing: Perform at least two washing steps with PBS/2% FBS to remove unbound antibody.

• Analysis parameters: Acquire at least 10,000 events per sample, setting appropriate gates based on forward/side scatter to identify the myeloid population.

• Controls: Always include isotype controls (mouse IgG2a) and known positive controls (myeloid leukemia samples) to establish proper gating strategies.

How should researchers interpret discordant results between M195 and other myeloid markers?

When faced with discordant results between M195 and other myeloid markers such as CD33, researchers should implement the following analytical approach:

• First, verify antibody performance with appropriate positive and negative controls to rule out technical issues.

• Consider antigen modulation effects, particularly in samples that have undergone ex vivo manipulation or preservation.

• Analyze the full immunophenotypic profile rather than relying on single markers; the pattern of multiple markers provides greater diagnostic accuracy than individual results.

• Remember that M195 binding does not correlate well with FAB classification of ANLL, so discrepancies with morphological classification are not uncommon.

• When possible, implement sequential testing with multiple antibodies to increase diagnostic confidence. The combined use of M195 and MY9 provides the highest specificity (98%) for diagnosing ANLL.

How can M195 antibody be utilized in studying hematopoietic progenitor cells?

M195 antibody serves as a powerful tool for studying hematopoietic progenitors through several advanced research applications:

• Progenitor identification: M195 has been demonstrated to bind to both granulocytic-monocytic and erythroid colony-forming units, making it valuable for identifying and isolating these progenitor populations.

• Differentiation pathway analysis: By coupling M195 with other lineage-specific markers in multiparameter flow cytometry, researchers can track myeloid differentiation stages from early progenitors to mature cells.

• Sorted cell functional assays: M195-positive cells can be isolated through FACS sorting for subsequent functional assays, including colony formation assays, differentiation potential studies, and transcriptional profiling.

• Normal versus leukemic progenitor comparison: M195 can help distinguish normal myeloid progenitors from leukemic counterparts, enabling comparative studies of signaling pathways and transcriptional networks.

What are the potential therapeutic applications of M195 antibody in leukemia treatment?

M195 antibody shows considerable promise for therapeutic applications due to its selective binding profile and limited reactivity with normal tissues:

• Antibody-directed therapy: M195's specificity for myeloid leukemia cells makes it a candidate for targeted therapy approaches in ANLL.

• Antibody-drug conjugate (ADC) development: Similar to established ADCs like Polivy and Adcetris, M195 could be conjugated with cytotoxic payloads such as MMAE or MMAF to selectively deliver these agents to leukemic cells.

• Radio-immunotherapy: M195 could be labeled with radioisotopes to deliver targeted radiation therapy to leukemic cells while sparing normal tissues.

• CAR-T cell therapy development: The target of M195 could potentially be used for chimeric antigen receptor design, directing engineered T cells specifically against myeloid leukemia cells.

• Minimal residual disease (MRD) detection: The high specificity of M195 makes it valuable for detecting small populations of residual leukemic cells after treatment.

How should researchers design validation experiments for M195 antibody in their laboratory?

To properly validate M195 antibody for research applications, implement this systematic validation protocol:

• Antibody titration: Determine optimal antibody concentration using a serial dilution approach with known positive cell lines (e.g., HL-60, KG-1) and primary ANLL samples.

• Specificity validation:

  • Positive controls: Test with myeloid leukemia lines and primary ANLL samples

  • Negative controls: Lymphoid leukemia lines and non-hematopoietic cell lines

  • Blocking studies: Perform with known CD33 antibodies to confirm epitope specificity

• Multi-platform validation: Confirm results across complementary techniques:

  • Flow cytometry (primary method)

  • Immunohistochemistry for tissue sections

  • Western blotting for molecular weight confirmation

  • Immunofluorescence microscopy for cellular localization

• Batch-to-batch consistency assessment: Test new antibody lots against previous lots to ensure consistent performance.

What considerations are important when designing multiparameter panels incorporating M195?

For effective multiparameter analysis incorporating M195, researchers should consider these critical design principles:

• Fluorochrome selection: Choose fluorochromes for M195 that don't overlap significantly with other critical markers in your panel. Consider brightness hierarchy - assign brightest fluorochromes to markers with lowest expression.

• Panel composition: For myeloid leukemia studies, consider combining M195 with:

  • Other myeloid markers: CD33, CD13, CD117

  • Progenitor markers: CD34, CD38

  • Differentiation markers: CD14, CD15

  • Lineage exclusion markers: CD3, CD19

• Control samples:

  • Fluorescence Minus One (FMO) controls to set proper gates

  • Compensation controls for each fluorochrome

  • Isotype controls to assess non-specific binding

• Titration in context: Re-titrate M195 in the full antibody panel context, as antibody performance can differ in multiplex conditions compared to single-staining.

How can researchers troubleshoot weak or variable M195 staining patterns?

When encountering inconsistent or weak M195 staining, implement this systematic troubleshooting approach:

• Sample quality assessment:

  • Ensure viability is >90% using viability dye

  • Verify sample freshness (process within 24 hours of collection)

  • Check for storage-related antigen degradation

• Protocol optimization:

  • Adjust antibody concentration (typically increase concentration for weak signals)

  • Modify incubation time and temperature (try 45-60 minutes at 4°C)

  • Test alternative permeabilization agents if studying intracellular epitopes

• Instrumentation checks:

  • Verify cytometer laser alignment and performance

  • Check PMT voltages and detector settings

  • Ensure appropriate filter sets for the fluorochrome used

• Biological considerations:

  • Evaluate cell cycle status (some antigens vary with cell cycle)

  • Test different cell preparation methods (enzymatic vs. mechanical dissociation)

  • Consider antigen modulation due to culture conditions or drug treatments

What are the analytical considerations when quantifying M195 expression levels across different leukemia subtypes?

For accurate quantification and comparison of M195 expression across leukemia subtypes:

• Standardization metrics:

  • Use antibody binding capacity (ABC) or molecules of equivalent soluble fluorochrome (MESF) rather than mean fluorescence intensity (MFI)

  • Include quantification beads in each run for standardization

  • Calculate stain index as: (MFI positive - MFI negative) / (2 × SD of negative population)

• Analytical approaches:

  • Set consistent gating strategies across all samples

  • Apply Boolean gating to analyze co-expression with other markers

  • Use dimensionality reduction techniques (tSNE, UMAP) for high-parameter data visualization

• Expression pattern analysis:

  • Classify expression as negative, dim, moderate, or bright

  • Document homogeneous versus heterogeneous expression patterns

  • Correlate expression levels with clinical parameters and outcomes

• Comparative analysis:

  • Include both percentage of positive cells and intensity metrics in reporting

  • Use statistical methods appropriate for non-parametric data when comparing groups

  • Consider hierarchical clustering to identify expression pattern similarities across subtypes

How should researchers interpret the relationship between M195 reactivity and leukemia prognosis?

When analyzing M195 reactivity in relation to clinical outcomes:

What experimental approaches can resolve the contradictory findings between M195 expression and FAB classification?

To address the noted discordance between M195 expression and traditional FAB classification:

• Integrative analysis methodology:

  • Combine morphological, cytochemical, immunophenotypic, and molecular data

  • Use machine learning algorithms to identify clustering patterns independent of predefined classifications

  • Implement consensus clustering approaches to identify robust subgroups

• Molecular correlation studies:

  • Correlate M195 expression with known genetic abnormalities

  • Perform RNA-seq on M195-positive versus M195-negative populations within the same FAB subtype

  • Use single-cell approaches to identify heterogeneity within morphologically similar populations

• Functional validation:

  • Compare in vitro drug sensitivity patterns between M195-positive and negative cells within the same FAB classification

  • Assess differentiation capacity following treatment with differentiating agents

  • Evaluate engraftment potential in xenograft models

• Longitudinal analysis:

  • Track M195 expression during disease progression and treatment

  • Correlate expression changes with evolving morphological and genetic features